A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes

Inclusion Criteria:

* Have type 2 diabetes
* Have a stable self-reported body weight (\<5% body weight change) for 90 days prior to screening
* Have a BMI of ≥27 kg/m2 at screening
* Have a history of at least 1 self-reported unsuccessful dietary effort to reduce body weight

Exclusion Criteria:

* Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed \>1 year before screening)
* Have a prior or planned endoscopic procedure and/or device-based therapy for obesity and/or type 2 diabetes (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
* Have type 1 diabetes
* Have taken any of the following within 90 days prior to screening

  * medications with direct amylin, glucagon-like peptide-1 (GLP-1) or glucagon-dependent insulinotropic polypeptide (GIP) receptor activity, including compounded therapies
  * dipeptidyl peptidase 4 (DPP-4) inhibitors, and
  * insulin
* Have had within 90 days prior to screening:

  * heart attack
  * stroke
  * coronary artery revascularization
  * unstable angina, or
  * hospitalization due to congestive heart failure
* Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure
* Have taken medications or alternative remedies intended for weight loss within 90 days of screening